Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Multiple cardiovascular outcomes trials (CVOTs) have shown the efficacy of GLP-1RAs in reducing major adverse cardiovascular events (MACEs) for high-risk patients. However, some CVOTs failed to demonstrate cardiovascular benefits. We analyzed the impact of GLP-1RA on cardiovascular and renal outcomes in patients with or without T2DM, with subgroup analysis based on sex, estimated glomerular filtration rate (eGFR), body mass index (BMI), and history of cardiovascular disease (CVD). A comprehensive database search for placebo-controlled RCTs on GLP-1RA treatment was conducted until April 2024. Data extraction and quality assessment were carried out, employing a robust statistical analysis using a random effects model to determine outcomes with log odds ratios and 95% confidence intervals (CIs). A total of 13 CVOTs comprising 83,258 patients were included. GLP-1RAs significantly reduced MACE (OR 0.86, 95% CI: 0.80 to 0.94, p<0.01) all-cause mortality OR 0.87, 95% CI: 0.82 to 0.93, p<0.001, CV mortality (OR 0.87, 95% CI: 0.81 to 0.94, p<0.001), stroke (fatal: OR 0.74, 95% CI: 0.56 to 0.96, p=0.03; non-fatal: OR 0.87, 95% CI: 0.79 to 0.96, p=0.005), coronary revascularization (OR 0.86, 95% CI: 0.74 to 0.99, p=0.023), and composite kidney outcome (OR 0.76, 95% CI: 0.67 to 0.85, p<0.001. GLP-1RA significantly reduced MACE in both sexes. Furthermore, GLP-1RA reduced MACE regardless of CVD history, BMI, and eGFR level. Significant reductions in MACE, overall and CV mortality, stroke, coronary revascularization, and composite kidney outcome with GLP-1RA treatment were noted across all subgroups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · BMJ · doi:10.1136/bmj.b2700 · Cited by 17,648
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 2×
“However, on closer inspection, the significant heterogeneity of our result may be because only Lincoff, et al. (2023) and Marso (2016) had significant results.”
Background2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C., Prescott, E., Storey, R. F., Deaton, C., Cuisset, T., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz425 · Cited by 7,166 · cited 1×
“Both the American College of Cardiology (ACC) and the European Society of Cardiology (ESC) recommend (class I, level of evidence A) the use of GLP-1RAs for patients with T2DM and chronic coronary syndrome/disease (CCS/CCD) in order to reduce MACE [38,39].”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485 · cited 2×
“…damage to reduce future CVD and total mortality, and both should be considered (class IIa, level of evidence B) for patients with T2DM without ASCVD, HF, or CKD based on estimated future risks (e.g. using the ADVANCE risk score or DIAL model) for adverse cardiovascular or cardiorenal outcomes [43].”
BackgroundResultInfluential2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333 · cited 1×
“…of GLP-1RAs for patients with STEMI and NSTE-ACS, the newly published 2023 ESC guidelines for the management of ACS mentioned that SGLT2 inhibitors (SGLT2i) and GLP-1RAs reduce the risk of new ACS events, HF, and renal impairment, and the reduction is independent of baseline HbA1c levels [40].”
BackgroundThe PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J., Bossuyt, P., Boutron, I., Hoffmann, T., mulrow, C., Shamseer, L., Tetzlaff, J., Akl, E., Brennan, S. E., et al. (2020) · doi:10.31222/osf.io/v7gm2 · Cited by 5,177
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 3×
“Ten RCTs [2,4-7, 14-18 14-18] reported MACE as the primary Nine RCTs [2,4-6,9,14-18] were done exclusively on patients with T2DM, and two [7,8] studies excluded patients with T2DM.”
BackgroundResultGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 1×
“The protective effect of GLP-1 can be due to its direct effect in GLP-1 receptors in the heart, independent of its ability to decrease body weight [32] and improve lipid metabolism which are acted upon by GLP-1 receptors in the brain and adipose tissues [33].”
BackgroundHernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669 · cited 4×
“…Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes) trial demonstrated that among patients with heart failure with preserved ejection fraction, obesity treat-ment with semaglutide led to reduced symptoms, limitations, and greater exercise function and weight loss [8,9].”
BackgroundInfluentialKristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642 · cited 3×
“…were made in the recent 2023 ESC Guidelines on Diabetes and Cardiovascular Diseases: GLP-1RAs such as liraglutide, semaglutide, or dulaglutide were recommended (class I, level of evidence A) among patients with T2DM and ASCVD to reduce CV risk, independent of baseline or target HbA1c [41].”
BackgroundResultInfluentialSattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · cited 2×
“Our findings are consistent with Sattar et al. (2019) [31], in their meta-analysis that reported similar cardio-vascular benefit among those who were given GLP-1 RA who had reduced eGFR ( < 60 ml/min) (HR 0.88, 95 % CI: 0.77 to 1.01) and preserved eGFR (HR 0.83, 95 % CI: 0.74 to 0.93) as compared…”
BackgroundResultInfluentialVirani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001168 · Cited by 1,598 · cited 1×
“Both the American College of Cardiology (ACC) and the European Society of Cardiology (ESC) recommend (class I, level of evidence A) the use of GLP-1RAs for patients with T2DM and chronic coronary syndrome/disease (CCS/CCD) in order to reduce MACE [38,39].”
BackgroundLiraglutide and renal outcomes in type 2 diabetes
Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616011 · Cited by 1,253
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Furtado, R. H. M., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038868 · Cited by 781 · cited 3×
“These antihyperglycemic agents have now been proven to reduce cardiovascular (CV) events among patients with and without DM [1].”
BackgroundResultInfluentialSemaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Kosiborod, M. N., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Treppendahl, M. B., Verma, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2313917 · Cited by 758 · cited 4×
“…Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes) trial demonstrated that among patients with heart failure with preserved ejection fraction, obesity treat-ment with semaglutide led to reduced symptoms, limitations, and greater exercise function and weight loss [8,9].”
BackgroundInfluentialMargulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.10260 · Cited by 706
Palmer, S. C., Tendal, B., Mustafa, R. A., Vandvik, P. O., Li, S., Hao, Q., Tunnicliffe, D., Ruospo, M., Natale, P., Saglimbene, V., et al. (2021) · BMJ · doi:10.1136/bmj.m4573 · Cited by 679
Sideri, S., Papageorgiou, S. N., & Eliades, T. (2018) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2018.01.003 · Cited by 388 · cited 1×
“This study was registered in the International Prospective Register of Systematic Reviews (PROSPERO) [13], with the identification number CRD42022360886.”
MethodGiugliano, D., Scappaticcio, L., Longo, M., Caruso, P., Maiorino, M. I., Bellastella, G., Ceriello, A., Chiodini, P., & Esposito, K. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01366-8 · Cited by 263 · cited 1×
“Giugliano, et al. (2021) [20] cited in a meta-analysis that patients with diabetes experienced greater reduction in MACE compared to non-diabetics, which is similar to our findings.”
ResultMarso, S. P., Baeres, F. M. M., Bain, S. C., Goldman, B., Husain, M., Nauck, M. A., Poulter, N. R., Pratley, R. E., Thomsen, A. B., & Buse, J. B. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.12.063 · Cited by 118
Lin, D. S.-H., Lee, J.-K., Hung, C.-S., & Chen, W.-J. (2021) · Diabetologia · doi:10.1007/s00125-021-05529-w · Cited by 108 · cited 1×
“Lin et al. (2021) [34] in their meta-analyses concluded that only GLP-1 RAs reduce the risk of stroke as compared to novel antidiabetic agents like Dipeptidylpeptidase 4 inhibitor (DPP-4i) and Sodium Glucose Transporter 2 inhibitor therapy (SGLT2i).”
BackgroundRuff, C. T., Baron, M., Im, K., O’Donoghue, M. L., Fiedorek, F. T., & Sabatine, M. S. (2022) · Nature Medicine · doi:10.1038/s41591-021-01584-3 · Cited by 102 · cited 1×
“Ten RCTs [2,4-7, 14-18 14-18] reported MACE as the primary Nine RCTs [2,4-6,9,14-18] were done exclusively on patients with T2DM, and two [7,8] studies excluded patients with T2DM.”
BackgroundCaruso, I., Cignarelli, A., Sorice, G. P., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2022) · Metabolites · doi:10.3390/metabo12020183 · Cited by 86
Campesi, I., Seghieri, G., & Franconi, F. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.06.007 · Cited by 25
Cited by
Gong, B., Li, C., Shi, Z., Wang, F., Dai, R., Chen, G., & Su, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1675552 · Cited by 36
Kalayci, A., Januzzi, J. L., Mitsunami, M., Tanboga, I. H., Karabay, C. Y., & Gibson, C. M. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf037 · Cited by 18
Inceu, G. V., Crăciun, A.-E., Ciobanu, D. M., Berchisan, A., Fodor, A., Bala, C., Roman, G., & Rusu, A. (2025) · Medicina · doi:10.3390/medicina61081343 · Cited by 3
Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes
(2025) · New England Journal of Medicine · doi:10.1056/nejmc2515117 · Cited by 2
Shekouh, D., Behboodi, M., Varmazyar, M., Khodadadiyan, A., Jochin, P., & Bazrafshan drissi, H. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08500-z · Cited by 1
Metadata
- Authors
- Rivera, F. B., Cruz, L. L. A., Magalong, J. V., Ruyeras, J. M. M. J., Aparece, J. P., Bantayan, N. R. B., Lara-Breitinger, K., & Gulati, M.
- Venue
- American Journal of Preventive Cardiology
- Publisher
- Elsevier BV
- Published
- 2024-06
- Volume
- 18
- Pages
- 100679
- ISSN
- 2666-6677 (ISSN-L)
- OpenAlex
- W4396691213
- Cited by
- 155
- References
- 31
- FWCI
- 14.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.